News|Articles|September 20, 2024
Reliable and Objective Antibody Analysis with the New Agilent ProteoAnalyzer System
Author(s)Agilent Technologies
This technical overview compares the characterization of NISTmAb using the ProteoAnalyzer with published NIST data obtained via traditional single capillary CE-SDS technology. The results show strong correlation with the reference data, confirming that the ProteoAnalyzer is a reliable tool for analytical workflows.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
2
Industrial-Scale Cell Therapy Automation Gains Traction with New Cellares Funding
3
HHS Releases New Guidance on Lowering Prescription Drug Prices Through DTC Programs
4
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
5